Haystack Oncology applies the next-generation of ctDNA detection technology to deliver industry-leading sensitivity and specificity for transformative MRD testing

Exact Ventures

Alexandria Venture Investments

Bruker

Catalio Capital Management

Haystack Oncology

A recent study added to the research supporting the clinical utility of circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing in patients with cancer. The article, “Circulating Tumor DNA: A promising biomarker for predicting recurrence in patients with BRAF-negative melanoma,” by Lauren Aoude and others, was published in the Journal of Molecular Diagnostics.  

The authors examined whether a ctDNA liquid biopsy (blood test) could be used to find targetable tumor mutations in patients who have late-stage melanoma, potentially leading to alternative treatments and improved outcomes for these patients.  

Key findings of the study: 
• ctDNA variants were detected in 85% of patients with BRAF-negative melanoma 
• Patients with stage IV melanoma who had low ctDNA concentrations had significantly better disease-specific survival and progression-free survival 
• Patients with a high ctDNA concentration and any detectable ctDNA variants had the worst prognosis 
• Changes in ctDNA concentration over time correlated with treatment response and disease progression 

The authors concluded that ctDNA liquid biopsies may be used to identify recurrent disease and detect targetable variants in patients with late-stage melanoma.  

Read the full study at https://hubs.la/Q027W0yn0

MRD testing demands the most sensitive ctDNA detection. Haystack MRD™ uses the next generation of ctDNA detection technology to see through the noise and uncover residual, recurrent, and resistant disease earlier. 

For circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) testing, the type of mutations tracked matters.  

 When designing a patient's personalized panel for an MRD test, Haystack's process is very deliberate in identifying and prioritizing truncal mutations—those mutations at the trunk of the “evolutionary tree” in the tumor.  

 By prioritizing mutations that drive the patient’s disease and that are present in both the primary tumor as well as any distant metastases, Haystack MRD can provide a more accurate picture of overall disease burden, resulting in more confident MRD results. 

Learn more at https://hubs.la/Q025sHTx0

Haystack Oncology is proud to be part of the 2023 European Society for Medical Oncology conference (#ESMO2023).  

Learn about our ultrasensitive #MRD technology. Add leverage to your drug discovery pipeline and accelerate biopharma innovation. Booth 586. Learn more at https://hubs.la/Q026fh160

Quest is proud to support #BreastCancerAwarenessMonth and recognize everyone involved in the fight against #breastcancer. According to the 
American Cancer Society, 1 in 8 women will be diagnosed with invasive breast cancer in their lifetime. Early detection can help save lives. As a single-source solutions provider, we offer tests for screening, diagnosis, treatment selection, and monitoring. Learn more: QuestHereditaryCancer.com

Haystack MRD™ uses a personalized, tumor-informed approach for minimal residual disease testing, meaning that a sample of each patient’s tumor is used to design an #MRD panel specific to that patient. In contrast, some MRD tests are tumor-naive, or tumor-agnostic, using the same panel of mutations for all patients.  

Read our blog post about the important differences between tumor-informed and tumor-naive MRD testing: https://hubs.la/Q021PSts0

Domain Not Resolving

Amazon

U.S. Server Location

Amazon Ohio Region

Wistia

Chief Executive Officer

Dan Edelstein

Executive Chairman

Isaac Ro

Finance and Administration

Joel Kaufman

Co-Founder and Chief Innovation Officer

Joshua Cohen

Associate Director, Market Access Strategy

Avneet Heer

Sr. Director Regulatory Affairs

Chris Pretzinger

Senior Director Research & Innovation

Christian Gloeckner

Director of Laboratory Operations

Hannah Quinn

Director, Medical Affairs

Hillary Sloane

Engineering

Justin DeGrazia

Jacob Vogelstein

George Petrocheilos

Chief Financial Officer

United States Acquired Companies With Fewer Than 100 Employees (Top 10K)

East Coast Acquired Companies With Fewer Than 1000 Employees (Top 10K)

United States Acquired Companies With More Than 50 Employees (Top 10K)

Maryland Companies (Top 10K)

Haystack Oncology, an oncology company, uses the most recent circulating tumor DNA detection technology to enhance the diagnosis of minimum residual disease and provide superior therapy decision-making information.

Series A - Haystack Oncology

Baltimore

Maryland

United States

North America

Haystack Oncology and Université de Montréal's affiliated hospital research centre, the CRCHUM, to Deploy Haystack MRD™ Technology in Research Study for Metastatic Colorectal Cancer

Quest Diagnostics' Haystack Oncology Forges New MRD Deal

EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy

Haystack Oncology, Lisata Therapeutics Collaborate on Pancreatic Cancer Therapy

Haystack MRD™ by Quest Diagnostics® on LinkedIn: #asco24

Quest Diagnostics (DGX) Advances in Cancer Research With New Deal

Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the ...

Baltimore's Haystack Oncology, TriSalus Life Sciences to develop liver cancer treatment

A tumor-informed, liquid biopsy test for detecting circulating tumor DNA (ctDNA) to identify residual, recurrent, or resistant disease in cancer patients.

A proprietary sequencing chemistry developed for the detection of low-abundance mutant DNA molecules, enhancing the sensitivity of ctDNA detection.

Haystack Oncology collaborates with biopharmaceutical companies and research organizations to use Haystack MRD technology in clinical trials for evaluating therapeutic response.

Strata Oncology is a company that offers a platform for precision oncology, including tumor sequencing and biomarker analysis.

Strata Oncology

Freenome is a biotechnology company focused on early cancer detection through blood-based tests using artificial intelligence and genomics.

Freenome

GRAIL is a healthcare company focused on early cancer detection through blood-based tests and deep sequencing technology.

GRAIL

Haystack Oncology offers a ctDNA detection technology for early identification of residual, recurrent, or resistant disease using a low-error, personalized MRD testing platform.

news impact assignment basic	general	Mar 4, 2024 1:45 PM	309ed989
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 4, 2024 1:45 PM	bd5c90a4
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	03bae661
crunchbase profile	general	Nov 22, 2024 9:30 AM	6f45036a
li profile	general	Mar 4, 2024 1:45 PM	b6620234
translate crunchbase fundingrounds	general	Nov 22, 2024 2:05 PM	9c006b03
peers	general
news basic	general	Mar 4, 2024 1:45 PM	607c0bb9
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:HAYSTACKONCOLOGY

Haystack Oncology